Henry Waxman actually said...

"This hearing today has very real implications for patients everywhere. How do we ensure that drug and device companies have the right incentives to discover important new treatments for disease?"

"We cannot rest on our laurels. We have an obligation to periodically reevaluate and adjust to account for the sweeping changes in the health sector."

"Thirty years ago, Representative Waxman coauthored the Hatch-Waxman Act, which updated our innovation ecosystem and made medications affordable for millions of Americans."

"In a biosimilars provision in the Affordable Care Act, we gave 12 years of exclusivity to biologics."